



Please amend the above-referenced application as follows:

✓
In the specification:

Please replace Table 4, at page 43 of the specification with the following Table 4:

Table 4: Apparent kinetic rate and affinity constants of D2E7 and biotinylated rhTNF

C¹

Experiment	K_a (M^{-1}, s^{-1})	K_d (s^{-1})	K_d (M)
1	1.33×10^5	9.58×10^{-5}	7.20×10^{-10}
2	1.05×10^5	9.26×10^{-5}	8.82×10^{-10}
3	3.36×10^5	7.60×10^{-5}	2.26×10^{-10}
Average	$1.91 \pm 1.26 \times 10^5$	$8.81 \pm 1.06 \times 10^{-5}$	$6.09 \pm 3.42 \times 10^{-10}$

C² Please insert drawings 1 to 9, filed herewith, after the last page of the specification.

In the claims:

Please cancel claim 1 without prejudice.

Please add the following new claims:

C³

74. (New) A pharmaceutical composition for treating a disorder in which TNF α activity is detrimental comprising an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNF α with a K_d of 1×10^{-8} M or less and a K_{off} rate constant of $1 \times 10^{-3} s^{-1}$ or less, both determined by surface plasmon resonance, and neutralizes human TNF α cytotoxicity in a standard *in vitro* L929 assay with an IC_{50} of 1×10^{-7} M or less, and at least one additional therapeutic agent.